Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Jiangxi Fushine Pharmaceutical Co Ltd
SZSE:300497
|
CN |
|
H
|
Heiq PLC
LSE:HEIQ
|
UK |
|
Shreyans Industries Ltd
NSE:SHREYANIND
|
IN |
Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. The company is headquartered in Jingdezhen, Jiangxi and currently employs 1,849 full-time employees. The company went IPO on 2015-12-22. The firm's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The firm distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.
Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of active pharmaceutical ingredient (API) and pharmaceutical intermediates. The company is headquartered in Jingdezhen, Jiangxi and currently employs 1,849 full-time employees. The company went IPO on 2015-12-22. The firm's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The firm distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.
